このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Newron Pharmaceuticals マネジメント

マネジメント基準チェック /34

Newron Pharmaceuticals'の CEO はStefan Weberで、 Jun2012年に任命され、の在任期間は 12.42年です。の年間総報酬は€ 510.00Kで、 93.1%給与と6.9%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.11%を直接所有しており、その価値はCHF 216.13K 。経営陣と取締役会の平均在任期間はそれぞれ12年と12.4年です。

主要情報

Stefan Weber

最高経営責任者

€510.0k

報酬総額

CEO給与比率	93.1%
CEO在任期間	12.1yrs
CEOの所有権	0.1%
経営陣の平均在職期間	12.1yrs
取締役会の平均在任期間	12.5yrs

経営陣の近況

Here's Why We Think Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Looks Fair for the time being

Apr 11

Recent updates

Here's Why We Think Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Looks Fair for the time being

Apr 11

We Think Newron Pharmaceuticals (VTX:NWRN) Has A Fair Chunk Of Debt

Nov 06

Shareholders May Be Wary Of Increasing Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Package

Apr 06

Newron Pharmaceuticals (VTX:NWRN) Has Debt But No Earnings; Should You Worry?

Apr 01

A Look At Newron Pharmaceuticals' (VTX:NWRN) Share Price Returns

Feb 25

CEO報酬分析

Newron Pharmaceuticals の収益と比較して、Stefan Weber の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Dec 31 2023	€510k	€475k	-€16m
Sep 30 2023	n/a	n/a	-€16m
Jun 30 2023	n/a	n/a	-€16m
Mar 31 2023	n/a	n/a	-€17m
Dec 31 2022	€498k	€429k	-€17m
Sep 30 2022	n/a	n/a	-€16m
Jun 30 2022	n/a	n/a	-€14m
Mar 31 2022	n/a	n/a	-€15m
Dec 31 2021	€510k	€414k	-€15m
Sep 30 2021	n/a	n/a	-€17m
Jun 30 2021	n/a	n/a	-€20m
Mar 31 2021	n/a	n/a	-€20m
Dec 31 2020	€582k	€403k	-€21m
Sep 30 2020	n/a	n/a	-€19m
Jun 30 2020	n/a	n/a	-€17m
Mar 31 2020	n/a	n/a	-€18m
Dec 31 2019	€691k	€440k	-€20m
Sep 30 2019	n/a	n/a	-€21m
Jun 30 2019	n/a	n/a	-€21m
Mar 31 2019	n/a	n/a	-€18m
Dec 31 2018	€647k	€430k	-€15m
Sep 30 2018	n/a	n/a	-€15m
Jun 30 2018	n/a	n/a	-€14m
Mar 31 2018	n/a	n/a	-€10m
Dec 31 2017	€563k	€418k	-€5m

報酬と市場: Stefanの総報酬 ($USD 547.62K ) は、 Swiss市場 ($USD 855.00K ) の同様の規模の企業の平均を下回っています。

報酬と収益: Stefanの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Stefan Weber (59 yo)

12.1yrs

在職期間

€510,000

報酬

Mr. Stefan Weber serves as the Chief Financial Officer and Finances and Administration Director at Duktus S.A. Mr. Weber has been the Chief Executive Officer of Newron Pharmaceuticals SpA since June 1, 201...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Stefan Weber	CEO & Executive Director	12.1yrs	€510.00k	0.11% € 163.2k
Roberto Galli	Chief Financial Officer	12.1yrs	データなし	0.013% € 20.1k
Filippo Moriggia	Vice President of Operations	2yrs	データなし	データなし
Ravi Anand	Chief Medical Officer	19.2yrs	€1.12m	0.22% € 335.8k
Laura Faravelli	Vice President of Business Development	less than a year	データなし	データなし

12.1yrs

平均在職期間

経験豊富な経営陣: NWRNの経営陣は経験豊富で経験豊富です（平均在職期間は12年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Stefan Weber	CEO & Executive Director	12.5yrs	€510.00k	0.11% € 163.2k
Patrick Langlois	Independent Non-Executive Director	16yrs	€78.00k	0.063% € 96.2k
Ulrich Köstlin	Independent Non-Executive Chairman	11.3yrs	€106.00k	0.21% € 322.8k
Luca Benatti	Non-Executive & Independent Director	10.3yrs	€68.00k	データなし
Ze' Seltzer	Member of Scientific & Clinical Advisory Board	no data	データなし	データなし
Charles Olanow	Member of Scientific Advisory Board	no data	データなし	データなし
Fabrizio Stocchi	Member of Scientific and Clinical Advisory Board	no data	データなし	データなし
Emilio Perucca	Member of Scientific & Clinical Advisory Board	no data	データなし	データなし
Paolo Marchettini	Member of Scientific & Clinical Advisory Board	no data	データなし	データなし
Marco Onofrj	Member of Scientific Advisory Board	no data	データなし	データなし
Abraham Lieberman	Member of Scientific Advisory Board	no data	データなし	データなし
Richard Murphy	Chairman of the Board of Statutory Auditors	22.5yrs	€13.00k	データなし

12.5yrs

平均在職期間

63yo

平均年齢

経験豊富なボード: NWRNの取締役会は経験豊富で経験豊富です ( 12.4年の平均在任期間)。

Newron Pharmaceuticals マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Newron Pharmaceuticals Appoints Margarita Chavez as Independent Board Member

Here's Why We Think Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Looks Fair for the time being

Newron Pharmaceuticals S.p.A. Appoints Margarita Chavez as Board Advisor

Newron Pharmaceuticals S.p.A., Annual General Meeting, Apr 18, 2023

Insufficient new directors

Insufficient new directors

Recent updates

Newron Pharmaceuticals S.P.A Reports Compelling Additional Data Documenting the Efficacy of Evenamide in Pivotal Study 008A in Poorly Responding Schizophrenia Patients

Forecast breakeven date pushed back to 2026

Newron Pharmaceuticals S.p.A. Announces Positive Top-line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide in Schizophrenia Patients

Newron Pharmaceuticals Appoints Margarita Chavez as Independent Board Member

Here's Why We Think Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Looks Fair for the time being

Consensus revenue estimates fall by 19%

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Forecast breakeven date pushed back to 2025

Newron Reports Exceptional One-Year Results of Study 014/15 with Evenamide in Treatment-Resistant Schizophrenia (TRS)

Newron Pharmaceuticals S.p.A. Completes Enrollment of Schizophrenia Patients in Potentially Pivotal Study 008A with Evenamide

Newron Pharmaceuticals S.p.A. to Report Fiscal Year 2023 Results on Mar 19, 2024

Forecast breakeven date pushed back to 2025

Forecast breakeven date moved forward to 2023

Newron Pharmaceuticals S.P.A. Presents New Data from Study 014/015 Evaluating Its Investigational Drug Evenamide for the Management of Treatment Resistant Schizophrenia

Newron Pharmaceuticals S.p.A. Appoints Margarita Chavez as Board Advisor

New minor risk - Market cap size

Forecast breakeven date moved forward to 2023

Full year 2022 earnings released: €0.98 loss per share (vs €0.83 loss in FY 2021)

Newron Reports Striking One-Year Interim Efficacy Results from Its Phase Ii Clinical Trial Evaluating Evenamide as Add-On Therapy for Patients with Treatment-Resistant Schizophrenia

Newron Pharmaceuticals S.p.A. Announces Striking Six-Month Interim Results from Its Exploratory Clinical Trial Evaluating Evenamide as Add-On Therapy for Patients with Treatment-Resistant Schizophrenia

Newron Pharmaceuticals S.p.A., Annual General Meeting, Apr 18, 2023

Insufficient new directors

First half 2022 earnings released: €0.48 loss per share (vs €0.51 loss in 1H 2021)

Newron Pharmaceuticals S.P.A. Presents Encouraging Interim Results for Evenamide in Patients with Treatment-Resistant Schizophrenia (Trs) At the 33Rd Cinp Hybrid World Congress of Neuropsychopharmacology

Insufficient new directors

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

We Think Newron Pharmaceuticals (VTX:NWRN) Has A Fair Chunk Of Debt

First half 2021 earnings released: €0.51 loss per share (vs €0.59 loss in 1H 2020)

Newron Pharmaceuticals S.p.A. Announces Paragraph IV ANDA Filings for Xadago® (safinamide) in the USA

Newron Pharmaceuticals S.p.A. Announces Paragraph IV ANDA filing for Xadago(R) (safinamide) in the USA

Shareholders May Be Wary Of Increasing Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Package

Newron Pharmaceuticals (VTX:NWRN) Has Debt But No Earnings; Should You Worry?

Consensus forecasts updated

Consensus forecasts updated

Full year 2020 earnings released: €1.18 loss per share (vs €1.13 loss in FY 2019)

Newron Pharmaceuticals S.p.A., Annual General Meeting, Apr 13, 2021

Newron and Zambon Sign Agreement for Potentially Pivotal Study with Safinamide in Parkinson’s Disease Patients

New 90-day high: CHF2.99

A Look At Newron Pharmaceuticals' (VTX:NWRN) Share Price Returns

New 90-day high: CHF2.95

Newron Pharmaceuticals Completes Enrollment of Explanatory Safety and Efficacy Study with Evenamide in Schizophrenia Patients

New 90-day high: CHF2.25

New 90-day high: CHF2.11

Analysts lower EPS estimates to -€1.17

First half earnings released

New 90-day low - CHF1.55

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34